(4-氟苯基)(1-哌嗪)甲酮 | 102391-98-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氟苯基)(1-哌嗪)甲酮
• 英文名称: 1-(4-fluorobenzoyl)piperazine
• 英文别名: (4-fluorophenyl)(piperazin-1-yl)methanone；(4-fluorophenyl)-piperazin-1-ylmethanone
• CAS: 102391-98-0
• 化学式: C₁₁H₁₃FN₂O
• mdl: MFCD01829194
• 分子量: 208.235
• InChiKey: OITKVXMAEXNRRK-UHFFFAOYSA-N

物化性质

• 沸点：
  353.8±37.0 °C(Predicted)
• 密度：
  1.191±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  (4-氟苯基)(1-哌嗪)甲酮 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 34.0h， 生成 1-(4-(3-(1H-indol-3-yl)propyl)piperazin-1-yl)-2-(4-(4-fluorobenzoyl)piperazin-1-yl)ethan-1-one
  参考文献：
  名称：

  Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer’s disease

  摘要：

  During the last decade, the one drug-one target strategy has resulted to be inefficient in facing diseases with complex ethiology like Alzheimer's disease and many others. In this context, the multitarget paradigm has emerged as a promising strategy. Based on this consideration, we aim to develop novel molecules as promiscuous ligands acting in two or more targets at the same time. For such purpose, a new series of indolylpropyl-piperazinyl oxoethyl-benzamido piperazines were synthesized and evaluated as multitarget-directed drugs for the serotonin transporter (SERT) and acetylcholinesterase (AChE). The ability to decrease beta-amyloid levels as well as cell toxicity of all compounds were also measured. In vitro results showed that at least four compounds displayed promising activity against SERT and AChE. Compounds 18 and 19 (IC50 = 3.4 and 3.6 mu M respectively) exhibited AChE inhibition profile in the same order of magnitude as donepezil (DPZ, IC50 = 2.17 mu M), also displaying nanomolar affinity in SERT. Moreover, compounds 17 and 24 displayed high SERT affinities (IC50 = 9.2 and 1.9 nM respectively) similar to the antidepressant citalopram, and significant micromolar AChE activity at the same time. All the bioactive compounds showed a low toxicity profile in the range of concentrations studied. Molecular docking allowed us to rationalize the binding mode of the synthesized compounds in both targets. In addition, we also show that compounds 11 and 25 exhibit significant beta-amyloid lowering activity in a cell-based assay, 11 (50% inhibition, 10 mu M) and 25 (35% inhibition, 10 mu M).These results suggest that indolylpropyl benzamidopiperazines based compounds constitute promising leads for a multitargeted approach for Alzheimers disease. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112368
• 作为产物：
  描述：

  tert-butyl 4-(4-fluorobenzoyl)piperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (4-氟苯基)(1-哌嗪)甲酮
  参考文献：
  名称：

  展望可药物治疗的人碳酸酐酶同工型的活性位点腔的边缘。

  摘要：

  我们报告了一系列的取代的4-（4-芳酰基哌嗪-1-羰基）苯磺酰胺（5a-s）的合成和生化评估，这些药物被开发为可药用的碳酸酐酶（CA）亚型的抑制剂，作为鉴定新疗法的工具。X射线晶体学证实，这类苯磺酰胺通过苯磺酰胺部分对金属离子的典型锚定和活性中心腔中部/顶部区域的尾部介导识别而与CA结合。化合物5e（R = 2-Cl）对脑表达的hCA VII具有相关的选择性。对于抑制剂5o（R = 3-NO2），发现对肿瘤表达的hCA IX / hCA XII的结合亲和力和选择性优于无处不在的hCA I / hCA II的最佳平衡。

  DOI：

  10.1021/acsmedchemlett.0c00062

文献信息

• Isoindolinyl-alkyl-piperazines
  申请人：Bristol-Myers Company

  公开号：US04585773A1

  公开（公告）日：1986-04-29

  The invention is generally concerned with isoindolinyl-alkylpiperazine compounds generally characterized by the formula ##STR1## wherein X is halogen or trifluoromethyl; n is an integer ranging from 2 to 5; Y is ##STR2## in which R.sub.1 is hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, cyano; R.sub.2 is hydrogen, halogen, lower alkyl, lower alkoxy; and R.sub.3 is hydrogen, cyano. These compounds are useful as diuretic and/or antihypertensive agents.

  这项发明通常涉及isoindolinyl-烷基哌嗪化合物，一般以以下式子为特征：##STR1## 其中X是卤素或三氟甲基；n是一个从2到5的整数；Y是##STR2## 其中R.sub.1是氢、卤素、较低烷基、较低烷氧基、三氟甲基、氰基；R.sub.2是氢、卤素、较低烷基、较低烷氧基；R.sub.3是氢、氰基。这些化合物可用作利尿剂和/或降压药。
• Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat
  申请人：Molecular Geriatrics Corporation

  公开号：US05658909A1

  公开（公告）日：1997-08-19

  Disclosed are compounds of formula I: ##STR1## or the pharmaceutically acceptable salts thereof wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar.sub.1 and Ar.sub.2 independently represent aryl groups; and Y is hydrogen; or Y and R.sub.1 or R.sub.2 together represent CH.sub.2 ; CH.sub.2 CH.sub.2 ; CH.sub.2 O; CH.sub.2 S forming a five or six membered ring and such ring may be optionally substituted with loweralkyl or phenyl; or pharmaceutically acceptable salts thereof, useful in the treatment of neoplastic diseases, and bacterial or fungal infections, and for preventing or decreasing the production of abnormally phosphorylated paired helical filament (PHF) epitopes associated with Alzheimer's Disease and, therefore for treating Alzheimer's Disease.

  揭示了以下式I的化合物：##STR1##或其药学上可接受的盐，其中X是羰基、磺酰基、亚甲基或亚甲基，或者亚甲基上带有可选择取代的苯基；Z是氮或CH；Ar.sub.1和Ar.sub.2分别代表芳基；Y是氢；或者Y和R.sub.1或R.sub.2一起代表CH.sub.2；CH.sub.2 CH.sub.2；CH.sub.2 O；CH.sub.2 S形成五元或六元环，该环可以选择性地取代为较低的烷基或苯基；或其药学上可接受的盐，用于治疗肿瘤性疾病，细菌或真菌感染，并用于预防或减少与阿尔茨海默病相关的异常磷酸化成对螺旋丝（PHF）表位的产生，因此用于治疗阿尔茨海默病。
• Substituted 1-aryl-3-piperazin-1'-yl propanones
  申请人：Molecular Geriatrics Corporation

  公开号：US05693804A1

  公开（公告）日：1997-12-02

  Disclosed are compounds of formula I: ##STR1## wherein X is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; Z is nitrogen or CH; Ar.sub.1 and Ar.sub.2 independently represent aryl groups; and Y is hydrogen; or Y and R.sub.1 or R.sub.2 together represent CH.sub.2 ;CH.sub.2 CH.sub.2 ; CH.sub.2 O; CH.sub.2 S forming a five or six membered ring and such ring may be optionally substituted with loweralkyl or phenyl; or the pharmaceutically acceptable salts thereof, useful in the treatment of neoplastic diseases, and bacterial or fungal infections, and in preventing or decreasing the production of abnormally phosphorylated paired helical filament (PHF) epitopes associated with Alzheimer's Disease and, therefore, useful for treating Alzheimer's Disease.

  揭示了以下式I的化合物：##STR1## 其中X是羰基、磺酰基、亚甲基或亚甲基，或者亚甲基上带有可选择取代的苯基；Z是氮或CH；Ar.sub.1和Ar.sub.2分别代表芳基；Y是氢；或者Y和R.sub.1或R.sub.2一起代表CH.sub.2；CH.sub.2 CH.sub.2；CH.sub.2 O；CH.sub.2 S形成五元或六元环，该环可以选择性地用较低烷基或苯基取代；或其药学上可接受的盐，用于治疗肿瘤性疾病，细菌或真菌感染，并预防或减少与阿尔茨海默病相关的异常磷酸化成对螺旋丝（PHF）表位的产生，因此，用于治疗阿尔茨海默病。
• 2-Phenylpyrroles as conformationally restricted benzamide analogs. A new class of potential antipsychotics. 2
  作者：Ineke Van Wijngaarden、Chris G. Kruse、Jan A. M. Van der Heyden、Martin T. M. Tulp

  DOI：10.1021/jm00118a011

  日期：1988.10

  A series of 2-phenylpyrrole Mannich bases was synthesized and screened in pharmacological models for antipsychotic activity and extrapyramidal effects. Structure modifications of 5-(4-fluorophenyl)-2-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]pyrrole (1), the prototype of a new class of sodium-independent atypical dopamine D-2 antagonists, resulted in 2-[[4-(7-benzofuranyl)-1-piperazinyl]methyl]-5

  合成了一系列2-苯基吡咯曼尼希碱，并在药理模型中筛选了抗精神病活性和锥体束外作用。5-（4-氟苯基）-2-[[4-（2-甲氧基苯基）-1-哌嗪基]甲基]吡咯的结构修饰（1），是新型的钠依赖性非典型多巴胺D-2拮抗剂的原型，产生2-[[[4-（7-苯并呋喃基）-1-哌嗪基]甲基] -5-（4-氟苯基）吡咯（15），它是比母体化合物更有效和选择性的D-2拮抗剂。阿朴吗啡诱导的攀爬行为具有出色的口服活性，并且有条件的回避反应测试以及没有僵住症，使得该化合物作为潜在的抗精神病药特别有前景，且诱发急性锥体外系副作用的可能性低。
• Synthesis and Biological Activity of <i>N</i>-Arylpiperazine-Modified Analogues of KN-62, a Potent Antagonist of the Purinergic P2X₇ Receptor
  作者：Pier Giovanni Baraldi、Maria del Carmen Nuñez、Anna Morelli、Simonetta Falzoni、Francesco Di Virgilio、Romeo Romagnoli

  DOI：10.1021/jm021049d

  日期：2003.4.1

  tyrosine derivative named KN-62 exhibits selective P2X(7) receptor-blocking properties. The present study was designed to evaluate the functional antagonistic properties of a novel series of KN-62-related compounds characterized by the presence of different phenyl-substituted piperazine moieties. Antagonistic activity of KN-62 derivatives was tested on HEK293 cells transduced with the human P2X(7) receptor

  P2X（7）受体参与与炎症相关的几个过程（细胞因子释放，NO生成，细胞内病原体的杀伤，细胞毒性）；因此，它可能是药理学干预的吸引人的目标。缺乏特异性和亚型选择性拮抗剂继续阻碍天然和重组P2X（7）受体的表征。但是，名为KN-62的酪氨酸衍生物表现出选择性的P2X（7）受体阻断特性。本研究旨在评估一系列新的KN-62相关化合物的功能拮抗特性，这些化合物的特征在于存在不同的苯基取代的哌嗪部分。在用人P2X（7）受体和单核细胞衍生的人巨噬细胞转导的HEK293细胞上测试了KN-62衍生物的拮抗活性，一种以该受体的高水平表达而闻名的细胞类型。所调查的生物学反应是跨膜的ATP依赖性Ca（2+）流入，溴化乙锭摄取和细胞因子白介素1β的分泌。KN-62的特征是存在苯基哌嗪部分，哌嗪氮与苯环（化合物61）之间存在一个碳原子的连接基增加了活性，而二碳化合物（化合物62）则降低了生物活性。活动十倍。同样，连接